The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers
Summary Two studies involving double‐blind group comparative trials in human volunteers compared the effects of intranasal nedocromil sodium (2·6 mg active drug per nostril, q.i.d.) with placebo on clinical symptoms and performance impairment associated with the common cold. In the first study volun...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental allergy 1990-01, Vol.20 (1), p.45-51 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 51 |
|---|---|
| container_issue | 1 |
| container_start_page | 45 |
| container_title | Clinical and experimental allergy |
| container_volume | 20 |
| creator | BARROW, G. I. HIGGINS, P. G. AL-NAKIB, W. SMITH, A. P. WENHAM, R. B. M. TYRRELL, D. A. J. |
| description | Summary
Two studies involving double‐blind group comparative trials in human volunteers compared the effects of intranasal nedocromil sodium (2·6 mg active drug per nostril, q.i.d.) with placebo on clinical symptoms and performance impairment associated with the common cold. In the first study volunteers were challenged with rhinoviruses (RV9 and RV14), and in the second study with respiratory coronavirus. In both studies, active and placebo groups of volunteers were demographically similar. Infection rates in both groups were also similar. There were no withdrawals resulting from unusual symptoms related to either treatment. In the rhinovirus study (19, placebo; 20, nedocromil sodium) daily symptom scores and daily mean nasal secretion weights were significantly lower in the nedocromil sodium‐treated group. In the coronavirus study (26, placebo; 27, nedocromil sodium) there was little difference in the severity of colds between the active and placebo‐treated groups, but trends favoured nedocromil sodium. In both studies the impairment of performance in volunteers who developed a cold was significantly less in those treated with nedocromil sodium than in those treated with placebo. |
| doi_str_mv | 10.1111/j.1365-2222.1990.tb02774.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7185334</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79656134</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5735-6ef80ce63b375bca46a754a416d6379df8d565255565fdbd31da54e85bcddfd63</originalsourceid><addsrcrecordid>eNqVkVuL1DAYhoMo67j6E4Qi4l1r0pwaQWEd1lVYD8iqlyFtEidj29SkXWf-vSlTit5pbpLwHsiXB4AnCBYoref7AmFG8zKtAgkBi7GGJeekONwBm1W6CzZQUJLzSpD74EGMewghpqI6A2clopRV1Qbsb3YmM9aaZsy8zVw_BtWrqNqsN9o3wXeuzaLXbuoy32e3LiRpGgYTsmDikK6jD8cspVKB6-ce5_uYjtlu6lRK-HbqR2NCfAjuWdVG82jZz8GXN5c327f59cerd9uL67yhHNOcGVvBxjBcY07rRhGmOCWKIKYZ5kLbSlNGS5oGoFbXGiOtKDFV8mptk-ccvDr1DlPdGd2YeaZWDsF1KhylV07-rfRuJ7_7W8lRRTEmqeDZUhD8z8nEUXYuNqZtVW_8FCUXjDL0D0ZECeWQlcn44mRMHxpjMHZ9DYJyRir3cuYmZ25yRioXpPKQwo__nGeNLgyT_nTRVWxUaxPAxsXVRiiCTIhke3my_XKtOf7HA-T28oLQlM9PeRdHc1jzKvyQjCdU8tuHK_m5fP9afNp-lQT_BqLu0Ik</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15457062</pqid></control><display><type>article</type><title>The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>BARROW, G. I. ; HIGGINS, P. G. ; AL-NAKIB, W. ; SMITH, A. P. ; WENHAM, R. B. M. ; TYRRELL, D. A. J.</creator><creatorcontrib>BARROW, G. I. ; HIGGINS, P. G. ; AL-NAKIB, W. ; SMITH, A. P. ; WENHAM, R. B. M. ; TYRRELL, D. A. J.</creatorcontrib><description>Summary
Two studies involving double‐blind group comparative trials in human volunteers compared the effects of intranasal nedocromil sodium (2·6 mg active drug per nostril, q.i.d.) with placebo on clinical symptoms and performance impairment associated with the common cold. In the first study volunteers were challenged with rhinoviruses (RV9 and RV14), and in the second study with respiratory coronavirus. In both studies, active and placebo groups of volunteers were demographically similar. Infection rates in both groups were also similar. There were no withdrawals resulting from unusual symptoms related to either treatment. In the rhinovirus study (19, placebo; 20, nedocromil sodium) daily symptom scores and daily mean nasal secretion weights were significantly lower in the nedocromil sodium‐treated group. In the coronavirus study (26, placebo; 27, nedocromil sodium) there was little difference in the severity of colds between the active and placebo‐treated groups, but trends favoured nedocromil sodium. In both studies the impairment of performance in volunteers who developed a cold was significantly less in those treated with nedocromil sodium than in those treated with placebo.</description><identifier>ISSN: 0954-7894</identifier><identifier>EISSN: 1365-2222</identifier><identifier>DOI: 10.1111/j.1365-2222.1990.tb02774.x</identifier><identifier>PMID: 2155688</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Administration, Intranasal ; Adolescent ; Adult ; Biological and medical sciences ; Common Cold - drug therapy ; Coronaviridae Infections - drug therapy ; Double-Blind Method ; Female ; Humans ; Infectious diseases ; Male ; Medical sciences ; Middle Aged ; Nedocromil ; Picornaviridae Infections - drug therapy ; Quinolones - administration & dosage ; Quinolones - therapeutic use ; Random Allocation ; Rhinovirus ; Viral diseases</subject><ispartof>Clinical and experimental allergy, 1990-01, Vol.20 (1), p.45-51</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5735-6ef80ce63b375bca46a754a416d6379df8d565255565fdbd31da54e85bcddfd63</citedby><cites>FETCH-LOGICAL-c5735-6ef80ce63b375bca46a754a416d6379df8d565255565fdbd31da54e85bcddfd63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2222.1990.tb02774.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2222.1990.tb02774.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,315,781,785,886,1418,4025,27928,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4510699$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2155688$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BARROW, G. I.</creatorcontrib><creatorcontrib>HIGGINS, P. G.</creatorcontrib><creatorcontrib>AL-NAKIB, W.</creatorcontrib><creatorcontrib>SMITH, A. P.</creatorcontrib><creatorcontrib>WENHAM, R. B. M.</creatorcontrib><creatorcontrib>TYRRELL, D. A. J.</creatorcontrib><title>The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers</title><title>Clinical and experimental allergy</title><addtitle>Clin Exp Allergy</addtitle><description>Summary
Two studies involving double‐blind group comparative trials in human volunteers compared the effects of intranasal nedocromil sodium (2·6 mg active drug per nostril, q.i.d.) with placebo on clinical symptoms and performance impairment associated with the common cold. In the first study volunteers were challenged with rhinoviruses (RV9 and RV14), and in the second study with respiratory coronavirus. In both studies, active and placebo groups of volunteers were demographically similar. Infection rates in both groups were also similar. There were no withdrawals resulting from unusual symptoms related to either treatment. In the rhinovirus study (19, placebo; 20, nedocromil sodium) daily symptom scores and daily mean nasal secretion weights were significantly lower in the nedocromil sodium‐treated group. In the coronavirus study (26, placebo; 27, nedocromil sodium) there was little difference in the severity of colds between the active and placebo‐treated groups, but trends favoured nedocromil sodium. In both studies the impairment of performance in volunteers who developed a cold was significantly less in those treated with nedocromil sodium than in those treated with placebo.</description><subject>Administration, Intranasal</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Common Cold - drug therapy</subject><subject>Coronaviridae Infections - drug therapy</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nedocromil</subject><subject>Picornaviridae Infections - drug therapy</subject><subject>Quinolones - administration & dosage</subject><subject>Quinolones - therapeutic use</subject><subject>Random Allocation</subject><subject>Rhinovirus</subject><subject>Viral diseases</subject><issn>0954-7894</issn><issn>1365-2222</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkVuL1DAYhoMo67j6E4Qi4l1r0pwaQWEd1lVYD8iqlyFtEidj29SkXWf-vSlTit5pbpLwHsiXB4AnCBYoref7AmFG8zKtAgkBi7GGJeekONwBm1W6CzZQUJLzSpD74EGMewghpqI6A2clopRV1Qbsb3YmM9aaZsy8zVw_BtWrqNqsN9o3wXeuzaLXbuoy32e3LiRpGgYTsmDikK6jD8cspVKB6-ce5_uYjtlu6lRK-HbqR2NCfAjuWdVG82jZz8GXN5c327f59cerd9uL67yhHNOcGVvBxjBcY07rRhGmOCWKIKYZ5kLbSlNGS5oGoFbXGiOtKDFV8mptk-ccvDr1DlPdGd2YeaZWDsF1KhylV07-rfRuJ7_7W8lRRTEmqeDZUhD8z8nEUXYuNqZtVW_8FCUXjDL0D0ZECeWQlcn44mRMHxpjMHZ9DYJyRir3cuYmZ25yRioXpPKQwo__nGeNLgyT_nTRVWxUaxPAxsXVRiiCTIhke3my_XKtOf7HA-T28oLQlM9PeRdHc1jzKvyQjCdU8tuHK_m5fP9afNp-lQT_BqLu0Ik</recordid><startdate>199001</startdate><enddate>199001</enddate><creator>BARROW, G. I.</creator><creator>HIGGINS, P. G.</creator><creator>AL-NAKIB, W.</creator><creator>SMITH, A. P.</creator><creator>WENHAM, R. B. M.</creator><creator>TYRRELL, D. A. J.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>199001</creationdate><title>The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers</title><author>BARROW, G. I. ; HIGGINS, P. G. ; AL-NAKIB, W. ; SMITH, A. P. ; WENHAM, R. B. M. ; TYRRELL, D. A. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5735-6ef80ce63b375bca46a754a416d6379df8d565255565fdbd31da54e85bcddfd63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Administration, Intranasal</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Common Cold - drug therapy</topic><topic>Coronaviridae Infections - drug therapy</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nedocromil</topic><topic>Picornaviridae Infections - drug therapy</topic><topic>Quinolones - administration & dosage</topic><topic>Quinolones - therapeutic use</topic><topic>Random Allocation</topic><topic>Rhinovirus</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BARROW, G. I.</creatorcontrib><creatorcontrib>HIGGINS, P. G.</creatorcontrib><creatorcontrib>AL-NAKIB, W.</creatorcontrib><creatorcontrib>SMITH, A. P.</creatorcontrib><creatorcontrib>WENHAM, R. B. M.</creatorcontrib><creatorcontrib>TYRRELL, D. A. J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and experimental allergy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BARROW, G. I.</au><au>HIGGINS, P. G.</au><au>AL-NAKIB, W.</au><au>SMITH, A. P.</au><au>WENHAM, R. B. M.</au><au>TYRRELL, D. A. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers</atitle><jtitle>Clinical and experimental allergy</jtitle><addtitle>Clin Exp Allergy</addtitle><date>1990-01</date><risdate>1990</risdate><volume>20</volume><issue>1</issue><spage>45</spage><epage>51</epage><pages>45-51</pages><issn>0954-7894</issn><eissn>1365-2222</eissn><abstract>Summary
Two studies involving double‐blind group comparative trials in human volunteers compared the effects of intranasal nedocromil sodium (2·6 mg active drug per nostril, q.i.d.) with placebo on clinical symptoms and performance impairment associated with the common cold. In the first study volunteers were challenged with rhinoviruses (RV9 and RV14), and in the second study with respiratory coronavirus. In both studies, active and placebo groups of volunteers were demographically similar. Infection rates in both groups were also similar. There were no withdrawals resulting from unusual symptoms related to either treatment. In the rhinovirus study (19, placebo; 20, nedocromil sodium) daily symptom scores and daily mean nasal secretion weights were significantly lower in the nedocromil sodium‐treated group. In the coronavirus study (26, placebo; 27, nedocromil sodium) there was little difference in the severity of colds between the active and placebo‐treated groups, but trends favoured nedocromil sodium. In both studies the impairment of performance in volunteers who developed a cold was significantly less in those treated with nedocromil sodium than in those treated with placebo.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>2155688</pmid><doi>10.1111/j.1365-2222.1990.tb02774.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-7894 |
| ispartof | Clinical and experimental allergy, 1990-01, Vol.20 (1), p.45-51 |
| issn | 0954-7894 1365-2222 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7185334 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Administration, Intranasal Adolescent Adult Biological and medical sciences Common Cold - drug therapy Coronaviridae Infections - drug therapy Double-Blind Method Female Humans Infectious diseases Male Medical sciences Middle Aged Nedocromil Picornaviridae Infections - drug therapy Quinolones - administration & dosage Quinolones - therapeutic use Random Allocation Rhinovirus Viral diseases |
| title | The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T16%3A00%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20intranasal%20nedocromil%20sodium%20on%20viral%20upper%20respiratory%20tract%20infections%20in%20human%20volunteers&rft.jtitle=Clinical%20and%20experimental%20allergy&rft.au=BARROW,%20G.%20I.&rft.date=1990-01&rft.volume=20&rft.issue=1&rft.spage=45&rft.epage=51&rft.pages=45-51&rft.issn=0954-7894&rft.eissn=1365-2222&rft_id=info:doi/10.1111/j.1365-2222.1990.tb02774.x&rft_dat=%3Cproquest_pubme%3E79656134%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15457062&rft_id=info:pmid/2155688&rfr_iscdi=true |